Theseus Pharmaceuticals, Inc.
THRXNASDAQHealthcare
$4.07
+$0.01(+0.12%)
Market Cap$181498998
P/E Ratio—
52W High$12.37
52W Low$2.05
Theseus Pharmaceuticals, Inc. (THRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
THRX · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2024Report Date: Mar 14, 2024EPS Actual
-$0.35
Est. -$0.33 · -6.1%
Revenue
—
Fiscal Period
Q1 FY2024
FY ends December
Report Date
Mar 14, 2024
After Market Close
▼ Miss EPS
THRX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2024 | Aug 10, 2024 | — | — | — | — | — | — |
| ◌ Q2 FY2024 | May 11, 2024 | — | — | — | — | — | — |
| ▼ Q1 FY2024 | Mar 14, 2024 | -$0.33 | -$0.35 | -6.1% | — | — | — |
| ▲ Q4 FY2023 | Nov 17, 2023 | -$0.35 | -$0.31 | +11.4% | — | — | — |
| — Q3 FY2023 | Aug 10, 2023 | -$0.34 | -$0.34 | +0.0% | — | — | — |
| ▲ Q2 FY2023 | May 11, 2023 | -$0.42 | -$0.34 | +19.1% | — | — | — |
| ▲ Q1 FY2023 | Mar 9, 2023 | -$0.44 | -$0.35 | +20.4% | — | — | — |
| ▼ Q4 FY2022 | Nov 3, 2022 | -$0.34 | -$0.38 | -11.8% | — | — | — |
Q3 FY2024
Aug 10, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
May 11, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Mar 14, 2024Miss
EPS Actual
-$0.35
EPS Est.
-$0.33
EPS Surpr.
-6.1%
Revenue
—
Q4 FY2023
Nov 17, 2023Beat
EPS Actual
-$0.31
EPS Est.
-$0.35
EPS Surpr.
+11.4%
Revenue
—
Q3 FY2023
Aug 10, 2023
EPS Actual
-$0.34
EPS Est.
-$0.34
EPS Surpr.
+0.0%
Revenue
—
Q2 FY2023
May 11, 2023Beat
EPS Actual
-$0.34
EPS Est.
-$0.42
EPS Surpr.
+19.1%
Revenue
—
Q1 FY2023
Mar 9, 2023Beat
EPS Actual
-$0.35
EPS Est.
-$0.44
EPS Surpr.
+20.4%
Revenue
—
Q4 FY2022
Nov 3, 2022Miss
EPS Actual
-$0.38
EPS Est.
-$0.34
EPS Surpr.
-11.8%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.80 | $1.54 | $1.24 | 0 |
| Q2 FY2024 | $1.57 | $1.34 | $1.08 | 0 |
| Q1 FY2024 | $1.84 | $1.58 | $1.27 | 0 |
| Q4 FY2023 | $-0.42 | $-0.36 | $-0.29 | 3 |
| Q3 FY2023 | $-0.39 | $-0.36 | $-0.32 | 6 |
| Q2 FY2023 | $-0.40 | $-0.34 | $-0.27 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2024 | Mar 14, 2024 | -6.1% | $4.06 | — | — |
| ▲ Q4 FY2023 | Nov 17, 2023 | +11.4% | $3.43 | $3.47 | +1.17% |
| ▲ Q3 FY2023 | Aug 10, 2023 | +0.0% | $3.19 | $3.27 | +2.51% |
| ▲ Q2 FY2023 | May 11, 2023 | +19.1% | $11.51 | $10.67 | -7.30% |
| ▲ Q1 FY2023 | Mar 9, 2023 | +20.4% | $8.49 | $8.54 | +0.59% |
| ▼ Q4 FY2022 | Nov 3, 2022 | -11.8% | $5.25 | $5.23 | -0.38% |
| ▼ Q3 FY2022 | Aug 11, 2022 | -3.5% | $8.38 | $7.80 | -6.92% |
| ▼ Q2 FY2022 | May 12, 2022 | -8.0% | $7.47 | $8.00 | +7.10% |
Q1 FY2024—
Report Date
Mar 14, 2024
EPS Beat/Miss
-6.1%
Price Before
$4.06
Price After
—
Q4 FY2023+1.17%
Report Date
Nov 17, 2023
EPS Beat/Miss
+11.4%
Price Before
$3.43
Price After
$3.47
Q3 FY2023+2.51%
Report Date
Aug 10, 2023
EPS Beat/Miss
+0.0%
Price Before
$3.19
Price After
$3.27
Q2 FY2023-7.30%
Report Date
May 11, 2023
EPS Beat/Miss
+19.1%
Price Before
$11.51
Price After
$10.67
Q1 FY2023+0.59%
Report Date
Mar 9, 2023
EPS Beat/Miss
+20.4%
Price Before
$8.49
Price After
$8.54
Q4 FY2022-0.38%
Report Date
Nov 3, 2022
EPS Beat/Miss
-11.8%
Price Before
$5.25
Price After
$5.23
Q3 FY2022-6.92%
Report Date
Aug 11, 2022
EPS Beat/Miss
-3.5%
Price Before
$8.38
Price After
$7.80
Q2 FY2022+7.10%
Report Date
May 12, 2022
EPS Beat/Miss
-8.0%
Price Before
$7.47
Price After
$8.00
Avg Beat Reaction-0.76%
Avg Miss Reaction-0.07%
Beat Rate4 / 8 quarters
Largest Move-7.30% (Q2 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: THRX ends December
Theseus Pharmaceuticals, Inc. (THRX) most recently reported earnings on March 14, 2024 for Q1 FY2024, posting EPS of $-0.35 — missing the analyst consensus of $-0.33 by -6.1%. The next THRX earnings date is expected around September 1, 2026.
Each quarter, investors track THRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. THRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
THRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
THRX earnings · 5 questionsTheseus Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. THRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; THRX historically reports after market close (AMC).
THRX earnings datewhen is THRX earningsTHRX next earnings datewhen does THRX report earningsTHRX earnings calendar
▸ Source: FMP · Theseus Pharmaceuticals, Inc. SEC filings · US GAAP · Theseus Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026